All In Biotech

Drug Trial Radar · NCT06561048

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 2, 2024

Primary completion

Nov 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Corvus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).

Conditions

  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Follicular T-Cell Lymphoma
  • Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Systemic Anaplastic Large Cell Lymphoma
  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell

Interventions

  • SoquelitinibDrug

    Soquelitinib 200 mg tablets will be taken by mouth two times a day

  • BelinostatDrug

    Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle

  • PralatrexateDrug

    Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: Up to 4 years post study treatment initiation

Locations

37 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine

    Miami, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC

    Chicago, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Roger Cancer Center University of Michigan Health

    Ann Arbor, Michigan · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Weill Cornell Medicine

    New York, New York · Recruiting

  • North Carolina Cancer Hospital

    Chapel Hill, North Carolina · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University; Knight Cancer Institute

    Portland, Oregon · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Washington Fred Hutch Cancer Center

    Seattle, Washington · Recruiting

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin · Recruiting

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • ICON Cancer Centre

    South Brisbane, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Flinders Medical Center

    Bedford Park, South Australia, Australia · Recruiting

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Victoria, Australia · Recruiting

  • Austin Hospital

    Heidelberg, Victoria, Australia · Recruiting

  • Epworth Healthcare

    Richmond, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Perth, Western Australia, Australia · Recruiting

  • BC Cancer Research Institute

    Vancouver, British Columbia, Canada · Recruiting

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada · Recruiting

  • The Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.